1. .....................................................................................................

2-3
1.1 ..............................................................................3-5

2. .........................5-6

2.1 .........6-10

2.2 .......................................10-14

2.3 ..................................................14-17

2.4 ................................................17-22

2.5 ......................................................22-25

2.6 ............................................................26-30

3. .................................................................................................31

4. .....................................................................32-35

PAGE 1
PAGE 2
1.

,
;
.

- (,

)
(-)

-(-)

PAGE 3
 :

1.1

- , ,

-

1-

450 , .

N, S P

2-

UDP
-
N-

PAGE 4


2.

I II
.

.
, . ,
,
. ,
. ,
, .
, .
, , , ,
, , , .

PAGE 5
2.1

.K
,

. ,
1 2 .

( ) .
10 mg / kg , 6 .
, 5 .
, ( , )
. ,
(CYP)
. 8 ,
40 . ,

.

, .388 ,
)
.
.
.
, ,
( ,
, , ).

PAGE 6
 ,
""
, , , ,
.

.
, P450 (CYP).
CYP .

. ,

.

.
1960- 1970-
,
.
, (CYPs),
CYPs ,
, 2D6,
34 ,

,
.

PAGE 7
 ,
, ,
CYPs. .
CYPs ,
CYPs .
,

.

,
.

.
.
,
.

,
.
,
. .

*Br J Clin Pharmacol. 2004 May

* M T Kinirons and M S O'Mahony-The Clinical Pharmacology of Ageing, edited by Dr A.A. Mangoni and colleagues, Department of
Healthcare for the Elderly, Guy's, King's and St Thomas' School of Medicine, Kings College London, London, UK.

P450-

.
;
,
.


. , 5
.
. , ,
CYP.
, CYP
- .
, ,
,
PAGE 8
 (5 )


.
,
, P450
.

April 2015 The FASEB Journal-

Yun Chen Tien1, Ke Lu2, Chad Pope,1Xiaochao Ma2 and Xiao-bo Zhong1-Department of Pharmaceutical Sciences, School of Pharmacy
University of Connecticut Storrs CT United States
Department of Pharmaceutical Sciences, School of Pharmacy University of Pittsburgh Pittsburgh PA United States

P450 (P450s) 75%

. ,
P450s, CYP3A4, CYP2B6, CYP2C9 CYP2C19,
.


, .

.
30
P450
.,

.
P450
, CYP3A11 CYP2C29,
.

P450
. ,
P450s , ,
P450 ,
.
,
CYP3A11, CYP2B10 CYP2C29, .
pH ,
P450
.
P450s
,

PAGE 9
- .
, ,
P450s. P450s

P450s
.
,

450.

April 2017 The FASEB Journal

Stephanie Piekos, Liming Chen and Xiao-bo Zhong-Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT

2.2.
.

. ,
( )
. .

.
.
.
. ,
: . ,
, ; ,
.
. ,
(-) - p-;
(R) (+) - m-.
(.. ) ,
( C-5 ) .
, .

. ,
, ,
. , :
( )
.
( , , ) , .
,
. ( , , , ),

PAGE 10
 .
. , ,
, .
, () .
,
40% .

. ,
.
. , in vitro
10
.

PAGE 11
2.2.1.
, ,
. .

( , N- ,
, -). ,
,
.
, ;
.
. ,
, . ,
. ,
. ,

. , e .
:

(MCD) .

(NASH)
Wistar, Long-Evans Sprague-Dawley , C57 / BL6 (n = 6
) MCD 4 .
(0.2% w / w) (0.3% w / w).

PAGE 12
 ( ) ,
( , , ),
: ()
.
MCD , (P
<0.001), (P <0.05)
ALT ( <0.005) . ( )
(P <0,05), ALT (P <0,05)
: (P <0,025) -
-. , Wistar
(P <0,05). MCD
, .
Wistar , C57 / BL6
(P <0.001), (
) (P <0.005) ,
( P <0.005), (P <0.005)
(
, P <0.005 P <0.01, )

MCD. , C57 / BL6
, ,
NASH.
November 2003

RICHARD KIRSCH,VIVIAN CLARKSON,ENID G SHEPHARD,DAVID A MARAIS,MOHAMED A JAFFER,VIVIENNE E

WOODBURNE,RALPH E KIRSCH,PAULINE DE LA M HALL-

20 -

() 20 - (20 -)
. AHR 20 -HSD

. , -
(WIM) , 20 -.
AHR 20 -HSD
.
. , AHR 20 -
HSD
, ,
.

Yakugaku Zasshi. 2001 Jan

Imamura Y1, Uchida A, Takada H, Otagiri M, Tsuchiya K.-

Faculty of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, Kumamoto 862-0973, Japan.

PAGE 13
 , , , ,
CYP

. ,
,
.
,
.

. CYPs,

. , CYPs
. CYP2E1
, .
, - CYP1A, -2C, -2D -3A


Expert Opin Drug Metab Toxicol. 2006 Dec

Martignoni M1, Groothuis GM, de Kanter R-

Nerviano Medical Sciences, Preclinical Development, Viale Pasteur 10, Nerviano (MI), Italy. marcella.martignoni@nervianoms.com

2.3

, CYP
, ,
, .

.
.
.
,

.
,
.
, ,
. ,
,
.
, .

( , 17-)
.
,
. ,
PAGE 14
 , , .
3, ,

. ,
,
.
. , ,
( ., [] , 3-)
( , , , TCDD), ,
.
, [] ,
CYP . .
, .
-
(t1 / 2 4.1 ) (ti / 2 7.2 ). ,
, , ,
.
.
,
(), ,
(7,7 11,7 )
(..
) .
CYP31 , ,

. CYP
. ,

CYP .
in vivo
,
P448

.

/ -
N-

.
,
.
.
(100 mg / kg, i.p)
(),
. ,

PAGE 15
 . L- (BSO),
,
,
ALT .
/ - ,
. N- (300 mg / kg, i.p)
/
.

,

. ,
,
. N-
/
/ ,
.
Adv Pharm Bull. 2014 Mar; 4(1): 2128. Published online 2013 Dec 23

Reza Heidari, Hossein Babaei, Leila Roshangar, and Mohammad Ali Eghbal- -Drug Applied Research Center, Tabriz University of
Medical Sciences, Tabriz, Iran

P450 1A2 in vitro in vivo.

(BER)
.
P450 (CYP) 1A2 in vitro in vivo.
-
CYP1A2 .
LC-MS /
MS-.
CYP1A2 mRNA HepG2
BER (4.5g / ml) (16.11 5.0 ,
), ( 4.5 1.98
, ) BER (10mg / kg / , ip) ex vivo. ,
CYP1A2 AUC0-t Cmax Ke t1 / 2
(p <0.05) in vivo.
BER CYP1A2
. , CYP1A2
6
.
BER in vivo
.

Life Sci. 2017 Sep 8.

Jiang B, Meng L, Zhang F, Jin X, Zhang G- Department of Pharmacy, Changzheng Hospital, Second Military Medical
University, Shanghai 200003, China.

PAGE 16
In vitro
HepG2

(BER) BER-
. ,
P450 (CYP) .

HepG2 in vitro. ,
, . , UPLC-MS / MS
BER HepG2 .
BER ,
CYP1A2 3A4 ,
CYP1A2 3A4 1000ng mL (-1).
CYP1A2 3A4 BER 500ng mL (-1) HepG2,
.
,
CYP1A2 3A4

J Ethnopharmacol. 2014 Dec 2

-Cui HM1, Zhang QY2, Wang JL2, Chen JL2, Zhang YL2, Tong XL3.- Guang'anmen Hospital, China Academy of Chinese Medical
Sciences, Beijing 100053, China.

2.4

, ,
. ,
, .
,
, ,

.
. , ( )
(S) (-) .
(
)
.
, . ,

. , , ,
.
- .
. , ,
CYP , , , CYP3A4.
PAGE 1
 , in vitro
in vivo . , , ,
--,
.
CYP P-
.
.

: -

,
P450 3A4 (CYP3A4) P450 3A5 (CYP3A5).
(GFJ), , ,
.

.



.
:
24 (AUC0-24),
(AUC0- ), (C max),
C max (T max), (T 1/2), (CL),

. RevMan 5.3 (
I2), .
57 ,
. [95% CI] GFJ
AUC0-24, AUC0-, C max T max
53 [43, 64], 53 [45, 62], 24 [12, 36] 19 [12, 26], . ,
AUC0- Cmax
[95% CI] 23 [13, 32] 25 [1, 50], , T 1/2 { -8
PAGE 2
[-15, -1]} .
.
, ,
,
.
Eur J Drug Metab Pharmacokinet. 2016 Dec

Sridharan K1, Sivaramakrishnan G2.

:
.

, .

.

.
,
.
,
.
, ,

.

PAGE 3
PAGE 4
Health Econ Rev. 2015 Dec;5
Kim H, House LA, Salois M

P2Y12 ,
P450 (CYP) 3A4. , CYP3A4,
.
.
, 200 ml
4 . 3, 10 mg
200 ml .
.

- (AUC (0-)) , 164%
(95% 122-220%, P = 0.008 ),
(C ()). C () AUC (0-)
51% (95% 32-84%, P =

PAGE 5
0.017) 74% (95% 60 -91%, P = 0.014)
(P <0.05). , VerifyNow
0-24 , 5 (95%
1-10 ) (P
= 0.034 ).
,
.

Br J Clin Pharmacol. 2015 Jul;

Holmberg MT1, Tornio A1, Hyvrinen H1, Neuvonen M1, Neuvonen PJ1, Backman JT1, Niemi M1.- Zhuhai Key Laboratory of Basic
and Applied Research in Chinese Medicine, Department of Bioengineering, Zunyi Medical University, Zhuhai, China.

2.5

.

.
.
,
,
; ,
, . ,
, , .
( )
.
.
CYP2D6 -
. 8% , 4%
1% .
CYP .
- -.
.

PAGE 6

.

-
,
.

.
SNP ,
- (CYP2C9, CYP2C19, CYP2D6, CYP2E1, NAT2,
UGT1A1 UGT1A3) 67 159
SNP- N- 2 (NAT2), -9796T> A R197Q
(p = 0.0016 p = 0.0007, ). NAT2 2 [A-A-A-G]
-9796T> R197Q (p = 0.0004).
,
. -9796A
NAT2 (p <0.01),
NAT2. 2
, :
.
NAT2

/ NAT2,
.

Pharmacogenomics. 2009 Nov

-Kim SH1, Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, Kim YS, Park JS, Kim BH, Jang IJ, Song J, Kim SH, Park HS, Min KU, Jee
YK.

PAGE 7
 A

() .
,
.
.
, .
, CA, VNTR RFLP 156
173 . ,
( / ).
173 .

MAOA .
MAOA-CA (P = 0.016) MAOA-VNTR (P =
0.004) . -
.

MAOA .

Iran Red Crescent Med J. 2015 Feb

;-Mohammad Reza Eslami Amirabadi,1 Sepideh Rajezi Esfahani,1 Rozita Davari-Ashtiani,2 Mojgan Khademi,2 Babak
Emamalizadeh,3 Abolfazl Movafagh,3 Said Sadr,2 Fariba Arabgol,2 Hossein Darvish,3,* and Katayoon Razjoyan2,*

,

.
Xp11.
uVNTR rs1137070, MAOA rs1799836 MAOB
- SNP 344
124 . uVNTR,
rs1137070 rs1799836 SNPs .
ANOVA
MAOB / rs1799836 ( = 4. 8 5 2 = 0. 0 0 9)
MAOA / uVNTR
( = 4. 2 3 6, = 0. 0 1 6) Bonferroni.

MAOA MAOB
. ,

.
344 (135 209 ), 267
Instituto Nacional de Psiquiatra Ramn de la Fuente (INPRF) 77
PAGE 8
 .
DSM-IVR
DIGS ( )
.
, ,
.
(SANS) [23]
() [24].
, , . , .
, . . . 124
(64 60 ),
DIS- .
, ,
[25].
INPRF
.
344 3 2. 6 9. 8 ( ..).
2 2. 1 7. 1 .
1 0. 1 5. 1 5. 6 4. 4
uVNTR rs1137070 MAOA rs1799836
MAOB .
- (> 0. 0 5). 3 4
( 1 3, ). uVNTR
. uVNTR, rs1137070 rs1799836 SNPs
.
,
MAOA MAOB
, .

, ,
. , ,


.

ISRN Psychiatry 27 February 2012-

Beatriz Camarena,1,2 Ana Fresn,3 Alejandro Aguilar,2 Ral Escamilla,4 Ricardo Saracco,4 Jorge Palacios,4 Alfonso
Tovilla,5 and Humberto Nicolini1,6

2.6

, , .
, -,

PAGE 9
. , , ,
,
. , ,
, , . ,
, ( ,
, , ), , ( , ,
) ,

(), ,
.
(3) (4)
.
1 .
120 [63 , 52,5%; 7.3 4.3 ,
(IQR): 7.0 (4-10 )] 1 .
, ,
3, 4 - ()
- 1, 3, 6 12. Mann-
Whitney U, (ANOVA) - Bonferroni
.

PAGE 10
 L- ,
(20 , 16.7%) 1, 3 6 ,
. ():
26.91, 95% (CI) 6.48-111.76, p <0.001] (: 3.69, 95% CI 1.05-
12.97, p = 0.042 )

L-
.

.

.

J Pediatr Endocrinol Metab. 2017 Apr

Kose E1, Guzel O2, Demir K3, Arslan N4.

:

?

.
P450, CYP2D6 CYP3A4, ,
, CYP1A2, .
, P-, ,
..

, , ,
.

.

PAGE 11
 , ,
.
,
.


in vitro in vivo . ,
CYP2C19
in vitro CYP2C19
.
, PBPK,
( , ) .
,
. ,
, ,
-
.

Drug Metab Dispos. 2013 Feb;

Nina Isoherranen and Kenneth E. Thummel

PAGE 12
PAGE 13
 : , , , ,
, , , ,

,

,
. ()

. CLT,
, 58 ( 30) ml / hr / kg
4 143 ml / hr / kg. ClT
; ; ; ; ;
; , , , ; .
NYBAID (
) ,
CLT.
, ,
. (r = -0.49) CLT.
. ,
(20-40 ) (83
29 ml / hr / kg), (> 40 )
(22 10 ml / /). ,
( ), ( ), ( )
, . ,
, ,
, ( ) .-


.
November 1979

William J. Jusko,Mark J. Gardner,Antoinette Mangione,Jerome J. Schentag,Jeffrey R. Koup,John W. Vance

3.

.
,
.
,
, .

PAGE 14
4.

1. Williams, R. T.: Detoxication Mechanisms, 2nd ed. New York, John Wiley & Sons, 1959.

2. Drayer, D. E.: Clin. Pharmacokinet. 1:426, 1976.

4. Jollow, D. J., et al.: Biological Reactive Intermediates. New York, Plenum Press, 1977.

5. Gillette, J. R., et al.: Annu. Rev. Pharmacol. 14:271, 1974.

6. Nelson, S. D., et al.: In Jerina, D. M. (ed.). Drug Metabolism Concepts. Washington, DC, American Chemical
Society, 1977, p. 155.

7. Testa, B., and Jenner, P.: Drug Metab. Rev. 7:325, 1978.

8. Low, L. K., and Castagnoli, N., Jr.: In Wolff, M. E. (ed.). Burger's Medicinal Chemistry, Part 1, 4th ed. New York,
Wiley-Interscience, 1980, p. 107.

9. Gill, E. W., et al.: Biochem. Pharmacol. 22:175, 1973.

10. Wall, M. E., et al.: J. Am. Chem. Soc. 94:8579, 1972.

11. Lemberger, L.: Drug Metab. Dispos. 1:641, 1973.

12. Green, D. E., et al.: In Vinson, J. A. (ed.). Cannabinoid Analysis in Physiological Fluids. Washington, DC, American
Chemical Society, 1979, p. 93.

13. Williams, R. T.: In Brodie, B. B., and Gillette, J. R. (eds.). Concepts in Biochemical Pharmacology, Part 2. Berlin,
Springer-Verlag, 1971, p. 226.

14. Rowland, M.: In Melmon, K. L., and Morelli, H. F. (eds.). Clinical Pharmacology: Basic Principles in Therapeutics,
2nd ed. New York, Macmillan, 1978, p. 25.

15. Benowitz, N. L., and Meister, W.: Clin. Pharmacokinet. 3:177, 1978.

16. Connolly, M. E., et al.: Br. J. Pharmacol. 46:458, 1972.

17. Gibaldi, M., and Perrier, D.: Drug Metab. Rev. 3:185, 1974.

18. Sinkula, A. A., and Yalkowsky, S. H.: J. Pharm. Sci. 64:181, 1975.

20. Peppercorn, M. A., and Goldman, P.: J. Pharmacol. Exp. Ther. 181:555, 1972.

21. Levy, G. A., and Conchie, J.: In Dutton, G. J. (ed.). Glucuronic Acid, Free and Combined. New York, Academic
Press, 1966, p. 301.

22. Testa, B., and Jenner, P.: Drug Metabolism: Chemical and Biochemical Aspects. New York, Marcel Dekker, 1976,
p. 419.

23. Powis, G., and Jansson, I.: Pharmacol. Ther. 7:297, 1979.

24. Mason, H. S.: Annu. Rev. Biochem. 34:595, 1965.

25. Hayaishi, O.: In Hayaishi, O. (ed.). Oxygenases. New York, Academic Press, 1962, p. 1.
PAGE 15
26. Mannering, G. J.: In LaDu, B. N., et al. (eds.). Fundamentals of Drug Metabolism and Disposition. Baltimore,
Williams & Wilkins, 1971, p. 206.

27. Sato, R., and Omura, T. (eds.): Cytochrome P-450. New York, Academic Press, 1978.

28. Omura, T., and Sato, R.: J. Biol. Chem. 239:2370, 1964.

30. Nelson, D. R., Koymans, L., Kamataki, T., et al.: Pharmacogenetics 6:1, 1996.

32. Claude, A.: In Gillette, J. R., et al. (eds.). Microsomes and Drug Oxidations. New York, Academic Press, 1969, p.
3.

34. Ortiz de Montellano, P. R.: Cytochrome P-450. New York, Plenum Press, 1986, p. 217.

35. Estabrook, R. W., and Werringloer, J.: In Jerina, D. M. (ed.). Drug Metabolism Concepts. Washington, DC,
American Chemical Society, 1977, p. 1.

36. Trager, W. F.: In Jenner, P., and Testa, B. (eds.). Concepts in Drug Metabolism, Part A. New York, Marcel Dekker,
1980, p. 177.

38. White, R. E., and Coon, M. J.: Annu. Rev. Biochem. 49:315, 1980.

39. Guengerich, F. P. (ed.): Mammalian Cytochromes P-450, vols. 1 and 2. Boca Raton, FL, CRC Press, 1987.

40. Schenkman, J. B., and Kupfer, D. (eds.): Hepatic Cytochrome P-450 Monooxygenase System. New York,
Pergamon Press, 1982.

41. Ioannides, C. (ed.): Cytochromes P450: Metabolic and Toxicological Aspects. Boca Raton, FL, CRC Press, 1996.

42. Guengerich, F. P.: Curr. Drug Metab. 2:93, 2001.

43. Daly, J. W., et al.: Experientia 28:1129, 1972.

44. Jerina, D. M., and Daly, J. W.: Science 185:573, 1974.

45. Kaminsky, L. S.: In Anders, M. W. (ed.). Bioactivation of Foreign Compounds. New York, Academic Press, 1985, p.
157.

46. Walle, T., and Gaffney, T. E.: J. Pharmacol. Exp. Ther. 182:83, 1972.

48. Whyte, M. P., and Dekaban, A. S.: Drug Metab. Dispos. 5:63, 1977.

49. Witkin, K. M., et al.: Ther. Drug Monit. 1:11, 1979.

50. Richens, A.: Clin. Pharmacokinet. 4:153, 1979.

51. Burns, J. J., et al.: J. Pharmacol. Exp. Ther. 113:481, 1955.

52. Y, T. F., et al.: J. Pharmacol. Exp. Ther. 123:63, 1958.

53. Black A. E., Hayes R. N., Roth B. D., et al.: Drug Metab. Dispos. 27(8):916, 1999.

54. Williams, M. C., et al.: Steroids 25:229, 1975.

PAGE 16
55. Ranney, R. E.: J. Toxicol. Environ. Health 3:139, 1977.

56. Lewis, R. J., et al.: J. Clin. Invest. 53:1697, 1974.

57. Daly, J.: In Brodie, B. B., and Gillette, J. R. (eds.). Concepts in Biochemical Pharmacology, Part 2. Berlin,
Springer-Verlag, 1971, p. 285.

58. Lowenthal, D. T.: J. Cardiovasc. Pharmacol. 2(Suppl. 1):S29, 1980.

59. Davies, D. S., et al.: Adv. Pharmacol. Ther. 7:215, 1979.

60. Dayton, P. G., et al.: Drug Metab. Dispos. 1:742, 1973.

61. Schreiber, E. E.: Annu. Rev. Pharmacol. 10:77, 1970.

62. Hollister, L. E., et al.: Res. Commun. Chem. Pathol. Pharmacol. 2:330, 1971.

63. Safe, S., et al.: J. Agric. Food Chem. 23:851, 1975.

64. Allen, J. R., et al.: Food Cosmet. Toxicol. 13:501, 1975.

65. Vinopal, J. H., et al.: Arch. Environ. Contamin. Toxicol. 1:122, 1973.

66. Hathway, D. E. (Sr. Reporter): Foreign Compound Metabolism in Mammals, vol. 4. London, Chemical Society,
1977, p. 234.

68. Daly, J., et al.: Arch. Biochem. Biophys. 128:517, 1968.

70. Lu, A. A. H., and Miwa, G. T.: Annu. Rev. Pharmacol. Toxicol. 20:513, 1980.

72. Maguire, J. H., et al.: Ther. Drug Monit. 1:359, 1979.

73. Harvey, D. G., et al.: Res. Commun. Chem. Pathol. Pharmacol. 3:557, 1972.

74. Stillwell, W. G.: Res. Commun. Chem. Pathol. Pharmacol. 12:25

75. www.pubmed.com

PAGE 17